BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 26193962)

  • 21. Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study.
    Loungnarath R; Causeret S; Bossard N; Faheez M; Sayag-Beaujard AC; Brigand C; Gilly F; Glehen O
    Dis Colon Rectum; 2005 Jul; 48(7):1372-9. PubMed ID: 15909071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center.
    Deraco M; Kusamura S; Laterza B; Favaro M; Fumagalli L; Costanzo P; Baratti D
    In Vivo; 2006; 20(6A):773-6. PubMed ID: 17203766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms.
    Choe JH; Overman MJ; Fournier KF; Royal RE; Ohinata A; Rafeeq S; Beaty K; Phillips JK; Wolff RA; Mansfield PF; Eng C
    Ann Surg Oncol; 2015 Aug; 22(8):2578-84. PubMed ID: 25582740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can a Benefit be Expected from Surgical Debulking of Unresectable Pseudomyxoma Peritonei?
    Delhorme JB; Elias D; Varatharajah S; Benhaim L; Dumont F; Honoré C; Goéré D
    Ann Surg Oncol; 2016 May; 23(5):1618-24. PubMed ID: 26678404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei.
    Sørensen O; Andersen AM; Larsen SG; Giercksky KE; Flatmark K
    Clin Exp Metastasis; 2019 Dec; 36(6):511-518. PubMed ID: 31541325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei in a liver-transplanted patient: a case report.
    Thorgersen EB; Melum E; Folseraas T; Larsen SG; Line PD
    World J Surg Oncol; 2018 Sep; 16(1):180. PubMed ID: 30185175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms.
    Yan TD; Links M; Xu ZY; Kam PC; Glenn D; Morris DL
    Br J Surg; 2006 Oct; 93(10):1270-6. PubMed ID: 16838392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
    Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
    Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome and surgical strategy in critical sites in cases of psuedomyxoma peritonei.
    Mahmoud AM; Hussein MM; Moneer MM
    J Egypt Natl Canc Inst; 2016 Dec; 28(4):249-255. PubMed ID: 27658904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytoreductive surgery plus perioperative intraperitoneal chemotherapy in pseudomyxoma peritonei: aspects of the learning curve.
    Andréasson H; Lorant T; Påhlman L; Graf W; Mahteme H
    Eur J Surg Oncol; 2014 Aug; 40(8):930-6. PubMed ID: 24656455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage].
    Ma RQ; Xia A; Zhai XC; Chen F; Xu HB
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):698-702. PubMed ID: 31550861
    [No Abstract]   [Full Text] [Related]  

  • 33. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Elias D; Honoré C; Ciuchendéa R; Billard V; Raynard B; Lo Dico R; Dromain C; Duvillard P; Goéré D
    Br J Surg; 2008 Sep; 95(9):1164-71. PubMed ID: 18690633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytoreductive surgery with intraperitoneal chemotherapy to treat pseudomyxoma peritonei at nonspecialized hospitals.
    Kitai T; Kawashima M; Yamanaka K; Ichijima K; Fujii H; Mashima S; Shimahara Y
    Surg Today; 2011 Sep; 41(9):1219-23. PubMed ID: 21874418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of an inguinal hernia in patients with pseudomyxoma peritonei.
    Sugarbaker PH
    Eur J Surg Oncol; 2017 Jun; 43(6):1083-1087. PubMed ID: 28131668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
    Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of Chemoresponse Assay in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy.
    Bhagwandin S; Naffouje S; Salti G
    Ann Surg Oncol; 2015 Aug; 22(8):2573-7. PubMed ID: 25572680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Kusamura S; Baratti D; Hutanu I; Gavazzi C; Morelli D; Iusco DR; Grassi A; Bonomi S; Virzì S; Haeusler E; Deraco M
    Eur J Surg Oncol; 2015 Aug; 41(8):1097-105. PubMed ID: 26026742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CA 19-9 to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with epithelial appendiceal mucinous neoplasms and peritoneal dissemination undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
    Kozman MA; Fisher OM; Rebolledo BJ; Valle SJ; Alzahrani N; Liauw W; Morris DL
    Eur J Surg Oncol; 2017 Dec; 43(12):2299-2307. PubMed ID: 28993033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?
    Sugarbaker PH
    Lancet Oncol; 2006 Jan; 7(1):69-76. PubMed ID: 16389186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.